A Single Center, Randomized,Open-label,Controlled, Three-arm Study to Evaluate the Effect of a New Combined Oral Contraceptive (COC) Containing 15 mg Estetrol (E4) and 3 mg Drospirenone (DRSP) and of Two Reference COCs Containing Either 30 mcg Ethinylestradiol (EE) and 150 mcg Levonorgestrel (LNG) or 20 mcg EE and 3 mg DRSP on Endocrine Function, Metabolic Control and Hemostasis During 6 Treatment Cycles
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 25 Mar 2017
At a glance
- Drugs Drospirenone/estetrol (Primary) ; Drospirenone/ethinylestradiol; Ethinylestradiol/levonorgestrel
- Indications Pregnancy
- Focus Pharmacodynamics
- Sponsors Estetra S.A.
- 21 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 15 Nov 2016 New trial record